Ignite Creation Date:
2025-12-26 @ 4:02 PM
Ignite Modification Date:
2025-12-30 @ 5:42 AM
Study NCT ID:
NCT04476706
Status:
NO_LONGER_AVAILABLE
Last Update Posted:
2021-02-03
First Post:
2020-07-16
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Canakinumab MAP in COVID-19 Pneumonia With CRS
Sponsor:
Novartis Pharmaceuticals
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Cytokine Release Syndrome in COVID-19-induced Pneumonia | View |